

DOCKET NO.: ALZA-0022
Application No.: 09/324,343
Office Action Dated: March 11, 2005

Do NOT enter 4/10/05
PATENT
REPLY FILED UNDER EXPEDITED
PROCEDURE PURSUANT TO
37 CFR § 1.116

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. **(Withdrawn)** A method of detecting the formulation orientation of a multi-layer capsule-shaped tablet, the method comprising the steps of:

detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer depending on the formulation orientation of the tablet, wherein at least one of the one or another formulation layers contains a colorant; and
determining the formulation orientation of the tablet on the basis of the color detected.

2. **(Withdrawn)** A method of detecting the formulation orientation of a multi-layer capsule-shaped tablet, the method comprising the steps of:

detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer depending on the formulation orientation of the tablet, wherein at least one of the one or another formulation layers contains a dark colorant; and
determining the formulation orientation of the tablet on the basis of the color detected.

3. **(Withdrawn)** A method of detecting the formulation orientation of a multi-layer capsule-shaped tablet, the method comprising the steps of:

detecting the color at a spot location on a side of the tablet corresponding to one or another formulation layer depending on the formulation orientation of the tablet, wherein at least one of the one or another formulation layers contains a dark colorant and another formulation layer contains a light colorant; and
determining the formulation orientation of the tablet on the basis of the color detected.

4. **(Withdrawn)** A method of detecting the formulation orientation of a multi-layer capsule-shaped tablet having an end portion containing a formulation layer that contains a drug ingredient and having an opposite end portion containing a formulation layer without a drug ingredient, the method comprising the steps of: